Positive results from Phase III lot consistency study of 20-valent pneumococcal conjugate vaccine (20vPnC) candidate

A Phase III study evaluating the consistency of immune responses elicited across three lots of a 20vPnC candidate in pneumococcal vaccine-naive adults (18-49 years) found equivalent responses across the lots for all 20 serotypes, with a safety profile similar to Prevnar 13®.


Biospace Inc.